{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:23:42Z","timestamp":1788931422281,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Stroke"],"abstract":"<jats:sec><jats:title>Background and hypothesis<\/jats:title><jats:p>At present, there are no medical interventions proven to improve functional recovery in patients with subacute stroke. We hypothesize that the intraparenchymal administration of CTX0E03, a conditionally immortalized neural stem cell line, linked with a standardized rehabilitation therapy regimen for the upper limb, would improve functional outcomes in patients 6\u201312 months after an index ischemic stroke.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>PISCES III was designed as a multicenter prospective, sham-controlled, outcome-blinded randomized clinical trial. Eligibility required a qualifying ischemic stroke 6\u201312 months prior to surgical intervention. Patients must be between 35 and 75 years of age and have residual moderate or moderately severe disability (mRS 3 or 4), with the preservation of some residual upper limb movement. All patients received a standardized regimen of home physical therapy following the intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study outcomes<\/jats:title><jats:p>The primary outcome measure is improvement in the modified Rankin Scale (mRS) of disability at 6 months post treatment. Secondary outcomes include assessment of activities of daily living (Barthel Index), functional mobility (Timed Up and Go; Fugl Meyer Assessment), neurological impairment (NIHSS), upper limb function (Chedoke Arm and Hand Inventory), as well as patient related quality of life and global rating scales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>PISCES III was designed as a randomized trial directly comparing the effects of intraparenchymal injection of a conditional stem cell line vs. sham procedure in patients with subacute stroke. This is one of the first studies of this type to include a standardized minimum rehabilitation protocol. As there are a limited number of studies evaluating invasive stem cell administration in the chronic setting of CNS injury, study design considerations are discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>, identifier NCT03629275.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fstro.2023.1182537","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T12:58:01Z","timestamp":1688475481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Methodological considerations in PISCES 3: a randomized, placebo-controlled study of intracerebral stem cells in subjects with disability following an ischemic stroke"],"prefix":"10.3389","volume":"2","author":[{"given":"Daniel T.","family":"Laskowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean I.","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie G.","family":"Pilitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott Y.","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng R.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Juel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Koltai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad J.","family":"Kolls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/jme.28.5.322","article-title":"Sham surgery controls: Intracerebral grafting of fetal tissue for parkinson's disease and proposed criteria for use of sham surgery controls","volume":"28","author":"Albin","year":"2002","journal-title":"J. Med. Ethics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00013614-200212000-00006","article-title":"Using standardized measures to meet the challenge of stroke assessment","volume":"18","author":"Anemaet","year":"2002","journal-title":"Top Geriatr Rehabil"},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1310\/JU8P-UVK6-68VW-CF3W","article-title":"Development of the chedoke arm and hand activity inventory: Theoretical constructs, item generation, and selection","volume":"11","author":"Barreca","year":"2004","journal-title":"Top Stroke Rehabil"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.apmr.2005.03.017","article-title":"Test-retest reliability, validity, and sensitivity of the chedoke arm and hand activity inventory: a new measure of upper-limb function for survivors of stroke","volume":"86","author":"Barreca","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"B5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/bmj.284.6329.1607","article-title":"Two-, six-, and 12-minute walking tests in respiratory disease","volume":"284","author":"Butland","year":"1982","journal-title":"Br. Med. J. (Clin Res Ed)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1161\/hs1101.098367","article-title":"Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats","volume":"32","author":"Chen","year":"2001","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1161\/STROKEAHA.120.031939","article-title":"The utility of domain-specific end points in acute stroke trials","volume":"52","author":"Cramer","year":"2021","journal-title":"Stroke"},{"key":"B9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0003-9993(03)00035-2","article-title":"Glycine Antagonist in Neuroprotection Americans I. Rasch analysis of a new stroke-specific outcome scale: the stroke impact scale","volume":"84","author":"Duncan","year":"2003","journal-title":"Arch. Phys. Med. Rehabil"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1877","DOI":"10.1212\/WNL.0000000000200154","article-title":"Association of modified rankin scale with recovery phenotypes in patients with upper extremity weakness after stroke","volume":"98","author":"Erler","year":"2022","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/0269215511423849","article-title":"Rodrigues-de-Paula F. Performance-based tests in subjects with stroke: outcome scores, reliability and measurement errors","volume":"26","author":"Faria","year":"2012","journal-title":"Clin Rehabil"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100404","article-title":"Recruitment challenges in stroke neurorecovery clinical trials","author":"Ferreira","year":"2019","journal-title":"Contemp. Clin. Trials Commun"},{"key":"B13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/1650197771331","article-title":"The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance","volume":"7","author":"Fugl-Meyer","year":"1975","journal-title":"Scand. J. Rehabil. Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/154596802401105171","article-title":"The fugl-meyer assessment of motor recovery after stroke: a critical review of its measurement properties","volume":"16","author":"Gladstone","year":"2002","journal-title":"Neurorehabil. Neural. Repair"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1161\/STROKEAHA.108.544585","article-title":"A self-administered Graded Repetitive Arm Supplementary Program (GRASP) improves arm function during inpatient stroke rehabilitation: a multi-site randomized controlled trial","volume":"40","author":"Harris","year":"2009","journal-title":"Stroke."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050444","article-title":"Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke","author":"Hassani","year":"2012","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of eq-5d (eq-5d-5l)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1474-4422(17)30046-7","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (masters): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"Hess","year":"2017","journal-title":"Lancet Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3727\/096368912X657936","article-title":"In vivo and in vitro characterization of the angiogenic effect of ctx0e03 human neural stem cells","volume":"22","author":"Hicks","year":"2013","journal-title":"Cell Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000262309","article-title":"Comparison of telephone and face-to-face assessment of the modified rankin scale","volume":"29","author":"Janssen","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0003-9993(95)80568-0","article-title":"Outcome and time course of recovery in stroke. Part ii: Time course of recovery. The copenhagen stroke study","volume":"76","author":"Jorgensen","year":"1995","journal-title":"Arch. Phys. Med. Rehabil"},{"key":"B22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0140-6736(16)30513-X","article-title":"Human neural stem cells in patients with chronic ischaemic stroke (pisces): A phase 1, first-in-man study","volume":"388","author":"Kalladka","year":"2016","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1212\/WNL.55.4.565","article-title":"Transplantation of cultured human neuronal cells for patients with stroke","volume":"55","author":"Kondziolka","year":"2000","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/sctm.18-0008","article-title":"Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase i safety study","volume":"7","author":"Laskowitz","year":"2018","journal-title":"Stem Cells Transl. Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1037\/t02366-000","article-title":"Functional evaluation: the barthel index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md State Med J"},{"key":"B26","author":"McDowell","year":"1996","journal-title":"Measuring Health: A Guide to Rating Scales and Questionnaires."},{"key":"B27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/014107680409701205","article-title":"Sham procedures and the ethics of clinical trials","volume":"97","author":"Miller","year":"2004","journal-title":"J R Soc. Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/jnnp-2019-322515","article-title":"Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (pisces-2)","volume":"91","author":"Muir","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12975-011-0095-z","article-title":"Intracranial delivery of stem cells","volume":"2","author":"Muir","year":"2011","journal-title":"Transl. Stroke Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000521916","article-title":"Toward generalizable trajectory planning for human intracerebral trials and therapy","author":"Olmsted","year":"2022","journal-title":"Stereot. Funct. Neuros"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20927-8","article-title":"An allogeneic 'off the shelf' therapeutic strategy for peripheral nerve tissue engineering using clinical grade human neural stem cells","author":"O'Rourke","year":"2018","journal-title":"Sci. Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.expneurol.2005.12.011","article-title":"A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke","volume":"199","author":"Pollock","year":"2006","journal-title":"Exp Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1161\/STROKEAHA.106.480723","article-title":"Initial experience of a digital training resource for modified rankin scale assessment in clinical trials","volume":"38","author":"Quinn","year":"2007","journal-title":"Stroke"},{"key":"B34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1056\/NEJMp1406388","article-title":"Sham controls in medical device trials","volume":"371","author":"Redberg","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12975-016-0482-6","article-title":"Stem cell therapy and administration routes after stroke","volume":"7","author":"Rodriguez-Frutos","year":"2016","journal-title":"Transl Stroke Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/STROKEAHA.109.571364","article-title":"Improving the reliability of stroke disability grading in clinical trials and clinical practice: the rankin focused assessment (rfa)","volume":"41","author":"Saver","year":"2010","journal-title":"Stroke"},{"key":"B37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/STROKEAHA.113.003379","article-title":"Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials","volume":"45","author":"Savitz","year":"2014","journal-title":"Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/scd.2017.0009","article-title":"Human neural stem cell therapy for chronic ischemic stroke: charting progress from laboratory to patients","volume":"26","author":"Sinden","year":"2017","journal-title":"Stem Cells Dev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/stem.1024","article-title":"Implantation site and lesion topology determine efficacy of a human neural stem cell line in a rat model of chronic stroke","volume":"30","author":"Smith","year":"2012","journal-title":"Stem Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1161\/STROKEAHA.116.012995","article-title":"Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1\/2a study","volume":"47","author":"Steinberg","year":"2016","journal-title":"Stroke"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-10-86","article-title":"C-mycertam transgene silencing in a genetically modified human neural stem cell line implanted into mcao rodent brain","author":"Stevanato","year":"2009","journal-title":"BMC Neurosci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pneurobio.2017.07.004","article-title":"Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms","volume":"158","author":"Stonesifer","year":"2017","journal-title":"Prog. Neurobiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/1545968309335978","article-title":"The neural stem cell line ctx0e03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion","volume":"23","author":"Stroemer","year":"2009","journal-title":"Neurorehabil. Neural. Repair"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the american heart association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2340\/16501977-0114","article-title":"Community ambulation in patients with chronic stroke: How is it related to gait speed?","volume":"40","author":"van de Port","year":"2008","journal-title":"J. Rehabil. Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1191\/0269215502cr534oa","article-title":"Improving the action research arm test: a unidimensional hierarchical scale","volume":"16","author":"van der Lee","year":"2002","journal-title":"Clin Rehabil"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the american heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1161\/STROKEAHA.119.028523","article-title":"Utility-weighted modified rankin scale scores for the assessment of stroke outcome: Pooled analysis of 20 000+ patients","volume":"51","author":"Wang","year":"2020","journal-title":"Stroke"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1161\/STROKEAHA.117.018290","article-title":"Cell therapy for chronic stroke","volume":"49","author":"Wechsler","year":"2018","journal-title":"Stroke"}],"container-title":["Frontiers in Stroke"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fstro.2023.1182537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T13:02:37Z","timestamp":1756472557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fstro.2023.1182537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":49,"alternative-id":["10.3389\/fstro.2023.1182537"],"URL":"https:\/\/doi.org\/10.3389\/fstro.2023.1182537","relation":{},"ISSN":["2813-3056"],"issn-type":[{"value":"2813-3056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"article-number":"1182537"}}